The use of enoxaparin as bridge to therapeutic INR after LVAD implantation

Table 3 Cumulative, index admission and 3-month follow-up odds ratios

Outcomes	Unadjusted OR (CI)	P	Adjusted OR (CI)^a	P
Cumulative
Bleeding events	1.12 (0.6–2.2)	0.73	1.2 (0.5–2.8)	0.62
CVA	0.39 (0.1–1.8)	0.22	0.42 (0.1–2.6)	0.35
Index
Bleeding events	1.01 (0.4–2.8)	0.99	0.91 (0.3–3.0)	0.88
CVA	0.42 (0.6–3.4)	0.42	0.67 (0.1–6.4)	0.73
Follow-up
Bleeding events	0.67 (0.3–1.6)	0.37	0.85 (0.3–2.3)	0.76
CVA	n/a	n/a	n/a	n/a

^aAdjusted for age, sex, race, type of LVAD, INTERMACS classification, type of cardiomyopathy, coronary artery disease prior stroke, chronic kidney disease, atrial fibrillation, hypertension, diabetes mellitus, obesity and obstructive sleep apnea
CI Confidence Interval, CVA Cerebrovascular Accident, OR Odds Ratio

ISSN: 1749-8090